🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Acute Myeloid Leukemia, in Relapse

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184Phase 144 sites📍 Phoenix📍 La Jolla📍 Los Angeles Kura Oncology, Inc. · Tests: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. NCT04275518Phase 114 sites📍 Beijing📍 Guangzhou📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG-115, Azacitidine, Cytarabine A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias NCT06994676Phase 111 sites📍 Duarte📍 Palo Alto📍 Tampa Crossbow Therapeutics, Inc. · Tests: CBX-250 Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen NCT06532084Phase 21 site📍 Saint Petersburg St. Petersburg State Pavlov Medical University · Tests: Sorafenib Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse NCT05270200Phase 1, Phase 21 site📍 Guanzhou Zhujiang Hospital · Tests: Azacitidine, Chidamide A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies NCT06906380n/a3 sites📍 Charlotte📍 Winston-Salem📍 Houston ARCE Therapeutics, Inc. · Tests: Non interventional study Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT NCT03793517Phase 2, Phase 31 site📍 Beijing Peking University People's Hospital · Tests: Decitabine, mBU/CY and ATG, mBU/CY Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation NCT06316960Phase 212 sites📍 Hefei📍 Hefei📍 Guangzhou Children's Hospital of Soochow University · Tests: Avapritinib, Azacitidine Injection, Decitabine Injection, Idarubicin Hydrochloride, Cytarabine SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07153068Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: supCD7 CART cells A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT06880354Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CLL1 and CD38 Dual-Target CAR-T Cell Injection Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS NCT06533761Phase 112 sites📍 Duarte📍 Aurora📍 Tampa Stelexis BioSciences · Tests: Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine, Azacitadine (AZA) Niclosamide in Pediatric Patients With Relapsed and Refractory AML NCT05188170Phase 11 site📍 Palo Alto Stanford University · Tests: Niclosamide Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04047641Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cladribine, Cytarabine, Idarubicin, Quizartinib Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome NCT03661307Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Decitabine, Quizartinib, Venetoclax Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites📍 San Francisco📍 Aurora📍 Atlanta Andrew E. Place, MD · Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia NCT05506332Phase 12 sites📍 Edegem📍 Roeselare University Hospital, Antwerp · Tests: Venetoclax, 6-mercaptopurine Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies NCT07584889Phase 1, Phase 21 site📍 Shenzhen Shenzhen University General Hospital · Tests: CAR-T cell Off-the-shelf CD123 CAR-NK for R/R AML NCT06201247EARLY Phase 11 site📍 Beijing Peking University People's Hospital · Tests: JD123 injection Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia NCT06613217Phase 11 site📍 Houston Pacylex Pharmaceuticals · Tests: zelenirstat Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04243785Phase 13 sites📍 Duarte📍 New York📍 Houston Edgewood Oncology Inc. · Tests: BTX-A51, Azacitidine HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML NCT05586074Phase 31 site📍 Hanzhou Sunshine Lake Pharma Co., Ltd. · Tests: Clifutinib, LoDAC, Azacitidine, Decitabine, Ara-C±IDA Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT04716452Phase 11 site📍 Charlottesville Keystone Nano, Inc · Tests: Ceramide NanoLiposome (Ceraxa) Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality NCT06370000Phase 41 site📍 Richmond Virginia Commonwealth University · Tests: Oral Azacitidine Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML NCT07355335Phase 12 sites📍 Boston📍 Boston Massachusetts General Hospital · Tests: Ziftomenib, Mezigdomide A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML NCT07751991Phase 15 sites📍 Duarte📍 New Haven📍 Grand Rapids Charm Therapeutics · Tests: CHM-029 Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia NCT06816134Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: TmBU conditioning Regimen, mBUCY conditioning regimen PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT NCT05772273NA1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Azacitidine, Donor lymphocyte infusion, Camrelizumab A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia NCT06387069Phase 353 sites📍 Hefei📍 Hefei📍 Hefei Hutchmed · Tests: HMPL-306 Regimen, Salvage Chemotherapy Regimen Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial NCT07101588Phase 41 site📍 Beijing Chinese PLA General Hospital · Tests: Ruxolitinib, Decitabine
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy